Medicus, Vol. 12 No. 2_Spolne bolesti, 2003.
Pregledni rad
Influence of Risperidone and Other Serotonin-Dopamine Antagonists on Weight Gain
Abdulah Kučukalić
Azijada Pašiček Srkalović
Marijana Oremuš
Edhem Rustempašić
Sažetak
This article shows the results of several clinical
studies that compared the effect of some serotonindopamine
antagonists on weight gain. The results of most
studies show the highest weight gain in the treatment with
olanzapine and clozapine, while the lowest weight gain was
reported with ziprasidone and risperidone. The results of the
study conducted in the University Psychiatric Clinic in Sarajevo,
which tested the efficacy of Pliva’s new generic risperidone
(Risset®, PLIVA), showed that the average weight gain
after a 4-week treatment with risperidone was 0.64 kg, i.e.
comparable to that reported in other studies. As far as the
effect on weight gain is concerned, risperidone can be
assigned to the group of serotonin-dopamine antagonists
with medium to lower potential, while olanzapine and clozapine
can be assigned to that with high potential. Ziprasidone
would be the only drug belonging to the group with low potential.
The article also shows the differences in the receptor
profile among dopamine antagonists, the theory about the
possible effect of H1 receptor binding on weight gain as well
as the leptin theory on weight gain. It also gives an overview
of results of several clinical studies dealing with the
increased concentration of blood glucose and lipids during
the use of serotonin-dopamine antagonists.
Ključne riječi
weight gain; risperidone; antipsychotic agents; leptin; receptors; histamine H1
Hrčak ID:
20589
URI
Datum izdavanja:
7.10.2003.
Posjeta: 3.508 *